Peripheral Vasopressor Administration: What recommendations promote patient safety?

When vasopressor therapy is indicated, clinicians must balance timely administration with patient safety. Consider the following case scenario:

A 72-year-old patient presents to the emergency department (ED) with suspected septic shock secondary to pneumonia. Despite fluid resuscitation, the patient remains hypotensive, and the ED provider orders a norepinephrine infusion to maintain a mean arterial pressure (MAP) range of 60-65 mm Hg. Because a central venous access device (CVAD) is not available, norepinephrine is initiated through one of the functioning peripheral IVs. The ED nurse reports that the ED provider does not believe a CVAD is needed, because the patient has two functioning peripheral intravenous catheters (PIVCs).

The receiving ICU nurse graduated from her nursing program six months ago and has three months of independent experience in the medical-surgical ICU. In this short time, she has experienced a variety of practices for peripheral vasopressor administration, including rapid placement of a CVAD, insertion of a midline peripheral catheter specifically for vasopressor administration, delays and pauses in vasopressor administration due to loss of IV access, and use of multiple short, superficial PIVCs for the full course of vasopressor therapy.

Even in her short career, she has observed variable outcomes from these diverse practices, including prompt, safe delivery of vasopressors; unnecessary CVAD placement; rapid loss of blood return in peripheral IVs; and early PIVC failure due to abnormalities such as leaking, blanching, pain and erythema. She receives the critically ill patient and continues to titrate the norepinephrine higher. She again wonders: Can vasopressors be safely administered through a peripheral IV? She asked her more experienced nurse colleagues this question and received answers as diverse as her experiences.

On the patient's admission to the ICU, she removes the suboptimal left wrist peripheral IV and, after three attempts, is unable to place a second peripheral IV for the continued fluids and later antibiotics. The novice nurse wonders and worries if she should call the provider to request a CVAD; if she will be able to replace the PIVC if it eventually fails; and what if the patient becomes agitated and dislodges it? She requests a consult from the charge nurse, but higher-priority patient care delays the response.

Can Vasopressors Be Safely Administered Through a Peripheral IV?

Historically, vasopressors have been a strong indicator for CVAD placement due to the increased risk of PIVC failure and patient harm, especially in patients requiring rapid escalation of a vasopressor dose or more than one vasopressor. However, the need to provide emergent vasopressor therapy in the absence of a CVAD drives the need to administer vasopressors peripherally. In addition, many patients may require only a short period of vasopressor infusion to enhance stability, making insertion of a CVAD an unnecessary risk. Thus, there is certainly a place for peripheral administration of vasopressors.

It is the duration of peripheral infusion and the parameters for safe administration that are the subject of intense scrutiny. Research on peripheral vasopressor administration has expanded rapidly in the last decade, based on:

• The urgency of treatment
• Reducing the placement of unnecessary CVADs

Vasopressors have also been used to justify avoidance of CVAD placement, even in patients requiring more than one and/or high doses of vasopressors. The situation has resulted in divergent practices, as experienced by the novice nurse in this scenario.

Understanding the Risks of Peripheral Vasopressor Administration

Central line-associated bloodstream infection (CLABSI) prevention is a critical quality metric due to associated patient morbidity and mortality. The intense focus on CLABSIs has created a shift to increased use of PIVCs to deliver medications that have historically required CVAD placement. As mentioned, growing evidence supports the safe administration of vasopressors via peripheral IVs when appropriate safeguards are in place. With reduced vessel blood flow, use of irritant and vesicant medications, shorter peripheral catheter length, challenges with dressing and securement integrity, and patient movement, PIVC failure (e.g., early removal due to a complication) is estimated to be as high as 30%-60%.

The most significant PIVC complications for consideration in peripheral vasopressor administration are:

• PIVC dislodgement (interruption of therapy)
• Phlebitis
• Extravasation

Long-term sequela of these complications include:

• Localized tissue damage
• Potentially leading to necrosis
• Vessel damage
• Thrombosis

The following significant vasopressor-related injuries have been reported:

• Skin grafting
• Amputation
• Nerve injury
• Upper extremity deep vein thrombosis

Due to the risk of patient harm and prevalent competency gaps in PIVC complication prevention, recognition, documentation and management, the peripheral route for vasopressor administration should be used only with intentional process improvement development to optimize patient safety.

Peripheral IV Catheter Failure and Extravasation

Care of the critically ill patient requires administration of many vesicant and irritant medications (see Table 1 for definitions), increasing the risk of complications when these medications are administered in the more vulnerable peripheral vascular access devices.

Peripheral intravenous devices include:

• Short, superficial PIVCs
• Long, often ultrasound-guided peripheral IVs
• Midline peripheral catheters (placed in the upper arm with the distal tip near the axillary fold)

The blood flow in these peripheral vessels may be as low as 10 mL/min with optimal blood flow at the distal tip far below the estimated blood flow in the superior vena cava at 1.8-2 L/min. The blood flow and hemodilution required to protect the vessel endothelium are even further reduced in the hemodynamically unstable patient.

In addition, the turbulence of blood flow after catheter placement and during flush and medication administration exposes the endothelium to injury through several factors, including:

• Subsequent PIVC insertion attempts
• Presence of nearby valves
• PIVC placement in suboptimal areas (e.g., flexion or above previous insertion attempts)

The risk of endothelial injury is further increased by the irritant properties of many critical care medications, such as norepinephrine, amiodarone and calcium chloride. Finally, mechanical irritation from catheter movement in and out of the vessel, which occurs readily in agitated patients and with PIVC placement in areas of flexion (e.g., antecubital fossa), increases the risk of phlebitis and extravasation injury.

Table 1: Vascular Access Infusate Characteristics and Complications

Monitoring Peripheral IV Sites for Patient Safety

Evidence-based standards of practice indicate that PIVC placement should, when clinically possible, avoid:

• Areas of flexion
• Diminished sensation
• Preexisting injury

Note: If placement in a suboptimal area is required during emergent resuscitation of the patient, that PIVC should be replaced in a more stable site as soon as clinically possible.

The frequency of PIVC site assessment should be based on the risks assessed, including:

• Patient's clinical scenario
  • Mentation
  • Vascular status
  • Clinical stability
• Infusate and vascular access device factors
  • Characteristics of the infusate
  • Specific vascular access device in use

A substantial factor that impacts PIVC failure is the patient's ability to report a change in the condition of the device (e.g., discomfort, edema). In the case of a PIVC placed in a suboptimal site, with a confused, unstable patient who has one vascular access option for lifesaving treatment, assessment should be performed every one to two hours to enhance early recognition of complications. This assessment would include inspection and palpation of the site. Consideration of the protection of this high-risk PIVC site with the use of an arm board would potentially prolong the dwell time until additional resources are available to replace the PIVC. In addition to site assessment (via visualization and palpation), patency assessment is challenging in this situation, since interruption of the infusion to assess blood return could result in further instability. This further reinforces the need to assess the PIVC site and to continue monitoring the expected effect of the medication as surrogate indicators of patency.

When Should a Central Venous Access Device Be Considered?

As our patient scenario continues, the norepinephrine infusion is now at 75% of the maximum dose with the MAP hovering just above the clinical target at a MAP of 60-65 mm Hg. The charge nurse assesses the patient and tells the nurse to escalate PIVC replacement to an expert nurse with ultrasound guidance, and to notify the provider about the increasing vasopressor requirement and that vascular access is suboptimal. Patient safety drives this need to avoid interruption of the required therapy if the PIVC fails and to facilitate prevention of PIVC complications such as phlebitis and extravasation.

Peripheral Vasopressor Administration Guidelines: Current Evidence

The 2026 Surviving Sepsis Campaign states the following with respect to peripheral vasopressor administration: "In adults with septic shock, we 'suggest' starting vasopressors peripherally to restore mean arterial pressure rather than delaying initiation until central venous access is secured. (conditional recommendation, very low certainty evidence) Remark: Data are insufficient to recommend a duration of use, dose, or access route (size of peripheral IV line or anatomic location). Midline catheters were not considered."

But what parameters provide enhanced patient safety in this area of practice? What guidance should be given to this novice nurse? The considerable variation in practice is a priority for organizations to address. With the mounting evidence, a strong recommendation is to develop a peripheral vasopressor protocol to guide this practice and to provide staff guidance as their patient's situation evolves, including criteria for escalation to a CVAD.

Thus far, much of the current evidence indicates low rates of adverse effects from peripheral administration of vasopressors. However, the evidence is often based on research conducted with retrospective (chart review) methodology, a substantial limitation given the well-established gaps in documentation regarding PIVC management. In fact, a recent systematic review/meta-analysis indicates that rates of adverse events reported in retrospective studies were consistently lower than those reported in higher-quality prospective studies, illustrating the lower quality of data in retrospective methodology. It is critical that prospective monitoring of outcomes occurs with PIVC management to ensure safe patient care is provided and that further high-quality, prospective research is conducted to further inform best practices. While a validated bundle of peripheral vasopressor administration interventions has yet to emerge from the mounting evidence, consider the following recommendations when creating an organizational peripheral vasopressor protocol based on current evidence.

Recommendations for Safe Peripheral Vasopressor Administration

Table 2: Peripheral Administration of Vasopressor Recommendations

Putting the Evidence Into Practice

As the scenario continues, the novice nurse escalates to an experienced nurse with ultrasound training who is able to establish a patent PIVC in a large forearm vein. The novice nurse transitions the vasopressor to this site. She also notifies the provider, who states that he will evaluate the need for CVAD placement. The novice nurse gives the family an update, noting that informed consent instructions will be available later, if needed, for potential CVAD placement.

After this shift, the novice nurse consults with her manager on the need to review the current evidence and the plan to collaborate with the facility's medication management leader to discuss developing a peripheral vasopressor protocol to improve PIVC guidance. She also develops a plan with her manager to create an audit form to monitor current practices and outcomes in peripheral vasopressor administration, establishing a data baseline for future process improvement.

Key Takeaways for Clinical Practice

In summary, peripheral vasopressor administration can improve patient outcomes, including reducing delays in needed therapy during resuscitation efforts when a CVAD is not yet present and for low-acuity patients requiring low-dose vasopressor therapy. Current evidence indicates that continued peripheral administration should be guided by a clearly defined protocol that instructs clinicians on optimal PIVC placement, vasopressor concentration and dose, assessment parameters and frequency, extravasation recognition and treatment, and criteria for escalation to CVAD placement.

Does your organization have a standardized protocol for peripheral vasopressor administration?